Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens

scholarly article

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2007PNAS..104.9788D
P356DOI10.1073/PNAS.0703584104
P932PMC publication ID1887550
P698PubMed publication ID17535926
P5875ResearchGate publication ID6300004

P50authorBrian R. MurphyQ65658906
P2093author name stringAlexander Bukreyev
Joshua M DiNapoli
Lijuan Yang
Peter L Collins
Siba K Samal
Subbiah Elankumaran
Alexander Kotelkin
P2860cites workParamyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisitedQ24531423
An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workersQ24684635
THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. II. RELATIONSHIP OF POLIOMYELITIS TO CUTTER VACCINEQ28190886
Identification of a novel coronavirus in patients with severe acute respiratory syndromeQ29615907
A novel coronavirus associated with severe acute respiratory syndromeQ29617553
Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.Q30357521
Review of accidents caused by incomplete inactivation of virusesQ30421151
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccineQ33230687
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceQ33696283
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Q33834543
Recombinant Newcastle disease virus as a vaccine vectorQ33850246
Newcastle disease and other avian paramyxovirusesQ33997603
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primatesQ34092801
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.Q34294068
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vectorQ34302198
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodiesQ34438091
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenicQ34465213
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle diseaseQ34624713
Nonsegmented negative-strand viruses as vaccine vectorsQ35139219
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunityQ36449078
Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirusQ37421234
Newcastle disease virus V protein is a determinant of host range restrictionQ39864222
Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunizationQ40108339
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccineQ40393493
Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in ratsQ40397313
Role of fusion protein cleavage site in the virulence of Newcastle disease virusQ40612116
Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuationQ40735127
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccineQ40940832
Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung.Q42098075
SARS vaccine protective in miceQ42555546
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humansQ43000500
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.Q44110039
Infectious diseases. Mounting lab accidents raise SARS fearsQ44274438
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c miceQ44961556
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferretsQ45501850
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.Q45622393
Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunityQ45736005
Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirusQ45858547
Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeysQ47812425
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.Q50787284
Effects of a SARS-associated coronavirus vaccine in monkeys.Q51639488
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirusQ57769050
P433issue23
P407language of work or nameEnglishQ1860
P921main subjectvaccineQ134808
Newcastle disease virusQ327082
immunizationQ1415366
vector-borne diseaseQ2083837
Newcastle diseaseQ11903425
emerging pathogenQ108429945
P304page(s)9788-9793
P577publication date2007-05-29
P1433published inProceedings of the National Academy of Sciences of the United States of AmericaQ1146531
P1476titleNewcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens
P478volume104

Reverse relations

cites work (P2860)
Q35112976A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen.
Q28261383Avian Paramyxovirus: A Brief Review
Q92640537Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates
Q39498475Chimeric rabies glycoprotein with a transmembrane domain and cytoplasmic tail from Newcastle disease virus fusion protein incorporates into the Newcastle disease virion at reduced levels
Q37297096Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans
Q34427532Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo
Q36949597Engineered intermonomeric disulfide bonds in the globular domain of Newcastle disease virus hemagglutinin-neuraminidase protein: implications for the mechanism of fusion promotion
Q89860924Engineering of Live Chimeric Vaccines against Human Metapneumovirus
Q36481537Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins
Q45354645Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120.
Q35886963Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus
Q35077454Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens
Q30427591Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
Q41919169Expression of transgenes from newcastle disease virus with a segmented genome
Q41325120Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings
Q36190495Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.
Q33490614Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses
Q39322307Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
Q33886452Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus
Q34457996Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies
Q34808109Infectious Bronchitis Virus as a Vector for the Expression of Heterologous Genes
Q40368584Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus
Q38953230Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy
Q36692742Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens
Q35883750Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
Q26744220Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines
Q57169065Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
Q39056306Newcastle disease vaccines-A solved problem or a continuous challenge?
Q35275117Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs
Q34059360Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice
Q40095159Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines.
Q35140435Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats
Q30382650Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Q37535829Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
Q38192846Newcastle disease virus: current status and our understanding
Q37033299Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses
Q47164675Pigeon paramyxovirus type 1 from a fatal human case induces pneumonia in experimentally infected cynomolgus macaques (Macaca fascicularis).
Q54967512Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.
Q97646303Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development
Q38266413RNA-based viral vectors
Q57989514Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus
Q52717318Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge.
Q24602728Recombinant Newcastle disease virus as a vaccine vector for cancer therapy
Q37133496Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model
Q41925230Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro
Q38559266Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases
Q37304963Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry
Q30380898Recombinant vectors as influenza vaccines.
Q40341670Rescue of a recombinant Newcastle disease virus strain R2B expressing green fluorescent protein
Q39074984Rescue of recombinant Newcastle disease virus from cDNA.
Q36190519Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response
Q28533970Retracted: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
Q35018292Retracted: Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques
Q33828508Retracted: Experimental Infection of Mice with Avian Paramyxovirus Serotypes 1 to 9
Q40200048Reverse Genetics of Newcastle Disease Virus
Q37386899Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses.
Q39877530Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector
Q37524036SARS vaccines: where are we?
Q35498222Safety and clinical usage of newcastle disease virus in cancer therapy
Q82975260Severe acute respiratory syndrome (SARS)
Q40592880The Threat and Response to Infectious Diseases (Revised).
Q93199923Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
Q42758269What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?

Search more.